Associate Professor; Director of Translational Research, Yale Pulmonary Vascular Disease Program, Internal Medicine; Co-Director of the Vascular Research T32 Training Program, Internal Medicine; Leadership Committee, 3CPR Council
We are interested in studying novel endothelial and vascular smooth muscle cell signaling pathways that are either disrupted or activated in the context of pulmonary arterial hypertension (PAH), a rare disease with high mortality (up to 45% at three years after diagnosis). We and others have shown that apelin-APJ signaling is disrupted in PAH patients and in experimental rodent models. Our ongoing studies are aimed at A) evaluating further downstream signaling mechanisms by which apelin mediates vascular homeostasis, B) role of microRNAs that are disrupted in PAH vasculature in the pathogenesis of disease, and C) identification and characterization of microRNA targeted signaling pathways such as FGF signaling as therapeutic targets.
Delayed production of neutralizing antibodies correlates with fatal COVID-19.Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie AL, Campbell M, Lee A, Chun HJ, Grubaugh ND, Schulz WL, Farhadian S, Dela Cruz C, Ring AM, Shaw AC, Wisnewski AV, Yildirim I, Ko AI, Omer S, Iwasaki A. Nat Med. 2021 May 5; 2021 May 5. PMID: 33953384.